II

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Retrieved on: 
Thursday, October 12, 2023

There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.

Key Points: 
  • There is a compelling need for new treatment options that can offer high and durable clinical response," said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
  • "Data presented at EADV showed that over 48 weeks many patients treated with bimekizumab achieved high thresholds of response.
  • These findings suggest that inhibition of IL-17F in addition to IL-17A represents a promising treatment approach in moderate-to-severe hidradenitis suppurativa."
  • "The bimekizumab Phase 3 clinical trial program in hidradenitis suppurativa included the more stringent clinical outcomes of HiSCR75, HiSCR90 and HiSCR100 in addition to the standard HiSCR50.

Intermedia Cloud Communications Honored with 2023 Frost & Sullivan Best Practices New Product Innovation Award in the Global UCaaS Archiving Market

Retrieved on: 
Thursday, October 12, 2023

SUNNYVALE, Calif., Oct. 12, 2023 /PRNewswire/ -- Intermedia Cloud Communications, a leading provider of intelligent cloud communications and collaboration solutions – including voice, video, chat, contact center, email, file management, productivity applications, and more – to businesses and the partners that serve them, announced it has been recognized with the prestigious Best Practices New Product Innovation Award from preeminent analyst firm, Frost & Sullivan, for its groundbreaking Intermedia Unite Archiving solution. Frost & Sullivan presents the New Product Innovation Award to companies at the forefront of innovation and growth in their respective industries, applying a rigorous analytical process to evaluate multiple nominees before determining the final award recipient.

Key Points: 
  • Frost & Sullivan presents the New Product Innovation Award to companies at the forefront of innovation and growth in their respective industries, applying a rigorous analytical process to evaluate multiple nominees before determining the final award recipient.
  • Intermedia Unite Archiving, which is available to customers of the all-in-one communications, collaboration, and contact center solution, Intermedia Unite, addresses this challenge by automating communications data collection and archiving to facilitate cross-channel data compliance, unified search, and reporting.
  • As Frost & Sullivan noted in its evaluation report, Unite Archiving has already distinguished itself amongst the competition since its launch earlier this year.
  • "We are deeply honored to receive the 2023 Frost & Sullivan Best Practices New Product Innovation Award for Intermedia Unite Archiving.

Industrial Laser Market to USD 2.64 billion growth between 2022 - 2027, Driven by growing demand from several industries - Technavio

Retrieved on: 
Wednesday, October 11, 2023

The potential growth difference for the industrial laser market between 2022 and 2027 is USD 2.64 billion.

Key Points: 
  • The potential growth difference for the industrial laser market between 2022 and 2027 is USD 2.64 billion.
  • Buy the full report here
    The increasing demand from several industries drives the industrial laser market growth.
  • The market witnesses substantial growth due to the growing demand for lasers in different industries such as automotive, aerospace, electronics, and healthcare.
  • Read Free Sample PDF Report Now
    Market Challenge - The emission of dangerous gases is a major challenge that hinders the industrial laser market growth.

Mill Creek Announces Groundbreaking of Modera Coral Springs Phase II

Retrieved on: 
Tuesday, October 10, 2023

CORAL SPRINGS, Fla., Oct. 10, 2023 /PRNewswire/ -- Mill Creek Residential, a leading developer, owner-operator and investment manager specializing in premier rental housing across the U.S., today announced it has broken ground on Modera Coral Springs Phase II, a contemporary mixed-use apartment community in the heart of Coral Springs. 

Key Points: 
  • Second Phase Will Add 353 Apartment Homes, Retail to Emerging South Florida Locale
    CORAL SPRINGS, Fla., Oct. 10, 2023 /PRNewswire/ -- Mill Creek Residential , a leading developer, owner-operator and investment manager specializing in premier rental housing across the U.S., today announced it has broken ground on Modera Coral Springs Phase II , a contemporary mixed-use apartment community in the heart of Coral Springs.
  • Coral Springs Phase I and II will be built to, and are pursuing, an NGBS Silver Certification.
  • With Phase II, we are not aiming to duplicate the original phase, but to offer a distinct set of amenities and a unique-but-similarly-refined living experience."
  • Firmly amidst the area's most prominent entertainment and employment centers, the community also offers near-direct access to The Walk of Coral Springs, Promenade at Coconut Creek, Tradewinds Park and many additional attractions.

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Retrieved on: 
Wednesday, October 4, 2023

NEW HAVEN, Conn., Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience, today provided an update on recent developments with its late-stage clinical programs as well as its patent portfolio for IGALMI™ (dexmedetomidine) sublingual film. These developments include meetings scheduled with the U.S. Food and Drug Administration (FDA) to discuss the TRANQUILITY and SERENITY III clinical programs and the receipt of two Notices of Allowance (NOAs) from the U.S. Patent and Trademark Office to extend method of use patent protection for sublingual dexmedetomidine.

Key Points: 
  • “The meetings with the FDA are critical components of our business strategy.
  • The briefing book submitted to FDA for the meeting includes results from 11 double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating the safety and efficacy of BXCL501.
  • The Company now has four U.S. patents claiming formulations of dexmedetomidine with exclusivity until 2039 currently listed in the Orange Book.
  • These patents further broaden the scope of intellectual property estate for IGALMI™ and for future potential indications.

Technicolor Creative Studios: Business Update and First Half 2023 Financial Results

Retrieved on: 
Monday, October 2, 2023

Net financial debt at nominal value amounted to €5773 million at the end of June 2023, compared with €650 million at the end of December 2022.

Key Points: 
  • Net financial debt at nominal value amounted to €5773 million at the end of June 2023, compared with €650 million at the end of December 2022.
  • IFRS net debt amounted to €613 million as of June 30, 2023, compared with €739 million as of December 31, 2022.
  • Therefore, Technicolor Creative Studios expects its rebound to be postponed by one year.
  • As a consequence of the above, the Company is publishing the following forward-looking assumptions:
    For 2023: revenue contraction and adjusted EBITDA after lease to decrease by c.€40m compared to first half 2023.

Morgan Stanley Bank, N.A. Receives Outstanding Rating for Community Reinvestment Initiatives

Retrieved on: 
Monday, October 2, 2023

The Bank received a rating of “Outstanding” for the Bank’s community reinvestment activities.

Key Points: 
  • The Bank received a rating of “Outstanding” for the Bank’s community reinvestment activities.
  • Both of the Firm’s national bank subsidiaries have achieved consistent “Outstanding” ratings based on the OCC’s review of community reinvestment activities.
  • “Morgan Stanley is very proud to have received, for the eighth time in a row, an “Outstanding” rating from the OCC for our community reinvestment work,” said Michael Pizzi, Head of U.S. Banks and Head of Technology.
  • Mike Mantle, Head of Community Development Finance at Morgan Stanley said, “Morgan Stanley continually looks for ways to make an impact in the communities we serve.

Gradiant Acquires H+E Group, a Leading European Water Technology Company, to Amplify Semiconductor and Industrial Water Expertise

Retrieved on: 
Monday, October 2, 2023

This acquisition underscores Gradiant's commitment to delivering leading-edge solutions for the semiconductor sector and represents the company's first footprint in Europe.

Key Points: 
  • This acquisition underscores Gradiant's commitment to delivering leading-edge solutions for the semiconductor sector and represents the company's first footprint in Europe.
  • (Graphic: Business Wire)
    By combining H+E Group’s domain expertise in semiconductor and industrial water with Gradiant's broad suite of end-to-end water treatment solutions, Gradiant is in a prime position to deliver innovative and tailored solutions to address the unique challenges faced by semiconductor manufacturers.
  • H+E Group’s long history and extensive 30,000 reference installations reflect its track record of successfully delivering high-quality water solutions.
  • This acquisition allows Gradiant to leverage these achievements and further establish itself as a leader in water solutions for the global semiconductor and industrial water market.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Monday, October 2, 2023

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 11 – 13, 2023, in Milan, Italy.
  • Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: https://apps.congrex.com/ectrims2023/en-GB/pag .
  • The late breaking abstract will be available on October 11, 2023.
  • Details of the presentations are outlined below.

Top Strike Announces 2024 First Quarter Financial Results ending July 31, 2023 and Corporate Update

Retrieved on: 
Friday, September 29, 2023

As at July 31, 2023, 57% of the Company's assets was directly related to US cannabis activities.

Key Points: 
  • As at July 31, 2023, 57% of the Company's assets was directly related to US cannabis activities.
  • The Company generated $149,995 (2022 - $97,942) in interest income from its short-term treasury deposits and two receivable notes.
  • Expenses for the three months ended July 31, 2023, were $236,900 (2022 - $277,992).
  • On August 16, 2023, the Company amended and restated its definitive agreement with Cannavative (the "A&R Definitive Agreement" or the "Transaction").